Angiotensin Receptor Blockers (ARBs) Global Market Report 2024

The angiotensin receptor blockers (arbs) market size has grown steadily in recent years. It will grow from $8.26 billion in 2023 to $8.62 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth observed during the historical period can be attributed to several factors, including the widespread prevalence of the hypertension epidemic, the demonstrated clinical efficacy of angiotensin receptor blockers (ARBs), the increasing burden of cardiovascular diseases, the renal protection offered by ARBs, the inclusion of ARBs as a first-line treatment in clinical guidelines, and the recognition of the cost-effectiveness of these medications. These factors collectively contributed to the historical growth and adoption of angiotensin receptor blockers in managing various medical conditions.

The angiotensin receptor blockers (arbs) market size is expected to see steady growth in the next few years. It will grow to $10.28 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The anticipated growth in the forecast period can be attributed to several factors, including the adoption of precision medicine approaches, a focus on combination therapies for improved treatment outcomes, the global expansion of the market for angiotensin receptor blockers (ARBs), the development of biomarker-based treatment strategies, government initiatives supporting hypertension management, and an increased awareness of hypertension and its complications. Key trends expected in the forecast period encompass the widespread adoption of telemedicine, increased investments in research and development, the impact of generic competition and patent expirations, the integration of digital health solutions for medication adherence, and the growing influence of biosimilar competition in the pharmaceutical landscape.

The rising prevalence of cardiovascular diseases is anticipated to drive the expansion of the angiotensin receptor blockers market in the foreseeable future. Cardiovascular diseases (CVD) encompass various conditions affecting the heart or blood vessels, often associated with factors such as atherosclerosis and an augmented risk of blood clot formation. Angiotensin receptor blockers function by reducing blood pressure and enhancing the heart's pumping ability through the relaxation of veins and arteries. This mechanism aids in minimizing the risk of cardiovascular diseases. Notably, projections by the American College of Cardiology in August 2022 indicate a substantial surge in cardiovascular risk factors and disease rates within the United States by 2060. Consequently, the increased incidence of cardiovascular diseases stands as a significant driver behind the growth of the angiotensin receptor blockers market.

The escalating prevalence of chronic kidney diseases is poised to fuel the growth trajectory of the angiotensin receptor blockers market in the coming years. Chronic kidney disease (CKD) denotes a prolonged condition marked by a gradual decline in kidney function. Angiotensin receptor blockers (ARBs) play a vital role in managing CKD by reducing blood pressure, providing renal protection, addressing diabetic nephropathy, and managing associated cardiovascular complications. Statistics from the Centers for Disease Control and Prevention in July 2022 revealed that approximately 15% or 37 million individuals in the United States were affected by kidney disease. Additionally, data from the Australian Institute of Health and Welfare showcased an increasing prevalence of kidney replacement therapy from 2019 to 2020, underscoring the growing burden of chronic kidney diseases. This escalating prevalence of CKD serves as a significant catalyst driving the expansion of the angiotensin receptor blockers market.

The escalating prevalence of hypertension diseases is poised to drive the expansion of the angiotensin receptor blockers (ARBs) market in the foreseeable future. Hypertension, characterized by persistently elevated blood pressure, finds treatment through medications such as angiotensin receptor blockers (ARBs), which operate by widening blood arteries, facilitating smoother blood flow. This increased prevalence of hypertension among the populace is expected to heighten the demand for angiotensin receptor blockers. For instance, data from the Centers for Disease Control and Prevention (CDC) in July 2023 highlighted hypertension as a leading cause of mortality in the US, accounting for 691,095 fatalities in 2021. Approximately 47% of US adults, totaling 116 million individuals, suffer from hypertension, with only 24% having it under control. An estimated 34 million individuals recommended medication may necessitate prescription initiation, emphasizing the substantial demand for treatment. This data underscores how the rising prevalence of hypertension diseases is fueling the growth of the angiotensin receptor blockers (ARBs) market.

Innovation stands as a pivotal trend propelling the popularity of products within the angiotensin receptor blockers market. Key industry players are keenly focused on developing groundbreaking solutions to bolster their market standing. Notably, in February 2021, Novartis AG, a Switzerland-based pharmaceutical giant, introduced Entresto (sacubitril/valsartan). This medication received an expanded indication from the United States Food and Drug Administration (FDA) to mitigate the risk of cardiovascular death and hospitalization among adult patients grappling with chronic heart failure. The clinical benefits of Entresto are particularly notable among individuals with lower-than-normal left ventricular ejection fraction (LVEF). It stands as the inaugural and solitary therapy sanctioned in the US for guideline-defined heart failure, encompassing both heart failure with reduced ejection fraction (HFrEF) and a substantial segment of heart failure with preserved ejection fraction (HFpEF) patients.

Major market contenders within the angiotensin receptor blockers (ARBs) domain are channeling their efforts toward innovation and securing approvals to fortify their market presence. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, serves as a medication targeted at heart failure treatment. In January 2021, Merck, a Germany-based pharmaceutical entity, attained approval from the U.S. Food and Drug Administration (FDA) for VERQUVO (vericiguat). VERQUVO is indicated for treating heart failure with reduced ejection fraction (HFrEF) in adult patients. This medication aids in vasodilation, reducing cardiac strain, and enhancing cardiac function, signifying a noteworthy advancement in heart failure management.

Major companies operating in the angiotensin receptor blockers (arbs) market report are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Movianto, Clinical Trial Logistics, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma.

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2023. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the angiotensin receptor blockers (arbs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products within the class of angiotensin receptor blockers (ARBs) include valsartan, losartan, irbesartan, azilsartan, and olmesartan. Losartan, for instance, is an ARB that not only treats hypertension but also reduces the risk of stroke and manages diabetic nephropathy. These medications find applications in various medical conditions, such as hypertension, cardiovascular diseases, kidney diseases, among others, and are utilized by end-users such as hospitals, specialty clinics, and ambulatory surgical centers.

The angiotensin receptor blockers (ARBs) market research report is one of a series of new reports that provides angiotensin receptor blockers (ARBs) market statistics, including angiotensin receptor blockers (ARBs) industry global market size, regional shares, competitors with a angiotensin receptor blockers (ARBs) market share, detailed angiotensin receptor blockers (ARBs) market segments, market trends and opportunities, and any further data you may need to thrive in the angiotensin receptor blockers (ARBs) industry. This angiotensin receptor blockers (ARBs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.